The “ Pharma Onshoring Cliff” is a part of tariff policy brought by the US government on 2nd April, 2026. This was designed to tackle the US dependence on foreign made drugs and their supplies. Under Section 232 of the Trade Expansion Act, the U.S. government declared that relying on foreign-made patented medicines and active pharmaceutical ingredients (APIs) is a national security risk.
What is Pharma Onshoring Cliff ?
The Pharma Onshoring Cliff is a suggested U.S. trade policy. Under this policy, pharmaceutical imports would be subject to rising tariffs unless manufacturers move their production to the United States.
The goal is to reduce U.S. reliance on foreign pharmaceutical supply chains, especially those based in China and India. This will help boost domestic production of medicines, active pharmaceutical ingredients (APIs), and essential medical supplies.
What is the reason behind it ?
In Washington, policy makers are starting to view pharmaceuticals not just as commercial products, but as strategic assets vital to public health, economic stability and national security. This policy shift has been accelerated by several developments which are as follows -
-
Exposure of Pharmaceutical Supply Chains- Due to the outbreak of the novel coronavirus pandemic, the vulnerabilities within the United States' pharmaceutical supply chains became apparent. There were lock-downs, closure of factories, export controls, and bottlenecks of transportation which impacted the movement of pharmaceutical products, active pharmaceutical ingredients (APIs), and other related supplies.
-
Geopolitical Tensions - The strain on the relationship between US and China has reshaped the industrial and trade policies of the US. Due to such conditions, the US has sought to diversify their supply chain by domestic production limiting the reliance on other countries.
-
Domestic Employment Generation - By raising the tariffs on the API and finished pharmaceuticals the US government intends to lower the consumption of imported drugs and encourage domestic production of the pharmaceutical which will help in domestic employment generation and this will help in strengthening the supply chain.
How the Tariff Escalator Works
The US government wants to increase its domestic production of pharmaceuticals. They designed the tariff measure in such a way that this will increase every year which will discourage imports of the pharmaceuticals.
This is how it works,
In the first year, there will be a 20% tariff on imported pharmaceutical products.
If the company persists in importing rather than transferring the production process to America, the percentage of the tariff will go up every year (from 20% to 40%, to 60%, etc., according to the set policy).
With the growth of the tariff, the cost of importing the medications increases.
In time, companies will find it more profitable to develop production plants in the USA.
Implications for India
-
High cost of exports: The tariffs will increase the cost of Indian pharmaceutical exports in America.
-
Loss of competitiveness: American pharmaceuticals will be more competitive compared to Indian imports.
-
Potential decrease in exports: Indian pharmaceutical companies may be unable to retain their market share, particularly in generics.
-
Incentive for manufacturing in America: Major Indian pharmaceutical companies may open and expand manufacturing units in America to evade tariffs.
-
Decreased margins: Those companies that decide to continue exporting products from India may have to bear the burden of increased tariff costs.
-
Diversification imperative: Indian pharmaceutical companies may diversify into other markets and focus on high-end value-added drugs like biosimilars.
Conclusion
The pharmaceutical tariff escalator being proposed by the government is just one manifestation of the current trend among U.S. policies that favor self-reliance in manufacturing. This trend poses both threats and opportunities for India. On the one hand, the increased tariffs can harm India’s pharmaceutical exports to America. However, on the other hand, it forces Indian businesses to explore different markets and innovate while increasing their international manufacturing presence. In the future, not only low-cost manufacturing but also a robust and flexible supply chain will be required.
The views expressed above belong to the author(s).